- Company
- 51 Jardiance patent-challenging generics released in 4 years
- by Kim, Jin-Gu Jan 8, 2021 06:20am
- Six more pharmaceutical companies are to evade the patents on Boehringer Ingelheim Korea’s antidiabetic sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin). As a result, total 51 companies would be able to avoid charges on infringing the product’s patent. The pharmaceutical industry source reported on Jan. 7 tha
- Company
- Korean-made novel drug Kanarb keeps on evolving
- by Kim, Jin-Gu Jan 8, 2021 06:20am
- Boryung Pharmaceutical’s star Kanarb (fimasartan) has added a new indication after a decade. Now the drug is indicated to reduce proteinuria in a hypertensive diabetic patient. In the highly saturated market for angiotensin II receptor blocker (ARB) for hypertension, Kanarb has found a new weapon to break through the stagnated growth.
- Company
- SK Bioscience and GSK signed a joint sale of 5 vaccines
- by Kim, Jin-Gu Jan 8, 2021 06:19am
- SK Bioscience has signed a joint sales contract with GSK for five vaccines. SK Bioscience announced on the 6th that it has signed a co-promotion contract for major vaccines with GSK to expand the domestic vaccine market. This is the content that SK Biosciences jointly sells and distributes vaccines developed by GSK in Korea. These prod
- Company
- Cyramza·Tarceva therapy is expected to be proposed
- by Eo, Yun-Ho Jan 8, 2021 06:19am
- It is noteworthy whether the first combination option of targeted anticancer drugs to enter insurance coverage in the first-line lung cancer therapy will be possible. According to related industries, first-line therapy for non-small cell lung cancer (NSCLC) VEGF receptor 2 antagonist Cyramza (Ramucirumab) and epithelial cell growth factor
- Company
- Mitsubishi Tanabe licensed to market narcolepsy drug Wakix
- by Jan 8, 2021 06:18am
- On Jan. 4, Mitsubishi Tanabe Pharma Korea (CEO : Yomogida Osamu) announced the Ministry of Food and Drug Safety (MFDS) has green lit a narcolepsy treatment Wakix Film Coated Tablet (pitolisant hydrochloride) on Dec. 30, 2020, for marketing in the South Korean market. Wakix is indicated to treat cataplexy in adult patients with narcolepsy
- Company
- SK Chemical's Ongentys can be prescribed at BIG 5
- by Eo, Yun-Ho Jan 6, 2021 06:20am
- SK Chemicals' Ongentys can be prescribed in general hospitals. According to related industries, the 3rd generation COMT inhibitor Ongentys (Opicapone) has passed the drug commitee (DC) of Big 5 hospitals such as SNUH, AMC, and Shinchon Severance Hospital. Ongentys, which was listed at a drug price of &8361;2,515 last October after domesti
- Company
- SK Bioscience loses MSD vaccines but nabs GSK vaccines?
- by Kim, Jin-Gu Jan 6, 2021 06:19am
- SK Bioscience is reportedly sealing the deal on commercializing four types of GSK vaccines in South Korea. When the deal is finalized, SK Bioscience would be able to fill the gap of four types of MSD vaccinea taken over by HK inno.N last year. According to a pharmaceutical industry source on Jan. 5, SK Bioscience and GSK Korea are i
- Company
- Patient copayment on Dupixent drops from 60% to 10%
- by Jan 6, 2021 06:18am
- From the break of the new year, the copayment burden on the patients prescribed with an atopic dermatitis treatment Dupixent would be reduced significantly. Sanofi Aventis Korea’s Dupixent would be applied with a special case reimbursement from Jan. 1, 2021 for the patients with severe case of atopic dermatitis. Accordingly, their copay
- Company
- Industry busy with M&A and investment for new opportunity
- by Chon, Seung-Hyun Dec 31, 2020 06:21am
- In the year 2020, many of South Korean pharmaceutical companies turned their eyes on new potential businesses. They reported major M&A news more than before. Some of them also took a bold step into bio company investment to find new opportunities. ◆GC and Celltrion ink notable M&A deals in hopes of finding new lucrative businesses
- Company
- Celltrion has applied for approval of COVID-19 treatment
- by Chon, Seung-Hyun Dec 31, 2020 06:20am
- Celltrion applied for accelerated approval of an antibody treatment COVID-19, the MFDS initiated a review. Celltrion announced on the 29th that it has applied to the MFDS for accelerated approval of CT-P59 (Regdanvimab), COVID-19 antibody treatment. An application for authorization was filed based on the recently ended global phase II clinic
